153 related articles for article (PubMed ID: 38261131)
21. Study types and reliability of Real World Evidence compared with experimental evidence used in Polish reimbursement decision-making processes.
Wilk N; Wierzbicka N; Skrzekowska-Baran I; Moćko P; Tomassy J; Kloc K
Public Health; 2017 Apr; 145():51-58. PubMed ID: 28359391
[TBL] [Abstract][Full Text] [Related]
22. Health technology assessment of medical devices: a survey of non-European union agencies.
Ciani O; Wilcher B; Blankart CR; Hatz M; Rupel VP; Erker RS; Varabyova Y; Taylor RS
Int J Technol Assess Health Care; 2015 Jan; 31(3):154-65. PubMed ID: 26044729
[TBL] [Abstract][Full Text] [Related]
23. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs.
Kolasa K; Zwolinski KM; Kalo Z; Hermanowski T
Orphanet J Rare Dis; 2016 Mar; 11():23. PubMed ID: 26965710
[TBL] [Abstract][Full Text] [Related]
24. Patient advocacy group involvement in health technology assessments: an observational study.
Single A; Cabrera A; Fifer S; Tsai J; Paik JY; Hope P
Res Involv Engagem; 2021 Nov; 7(1):83. PubMed ID: 34823610
[TBL] [Abstract][Full Text] [Related]
25. Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework.
Angelis A; Linch M; Montibeller G; Molina-Lopez T; Zawada A; Orzel K; Arickx F; Espin J; Kanavos P
Soc Sci Med; 2020 Feb; 246():112595. PubMed ID: 31874372
[TBL] [Abstract][Full Text] [Related]
26. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
[TBL] [Abstract][Full Text] [Related]
27. Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations.
Binder L; Ghadban M; Sit C; Barnard K
Curr Oncol; 2022 Mar; 29(3):1514-1526. PubMed ID: 35323327
[TBL] [Abstract][Full Text] [Related]
28. What Influences Recommendations Issued by the Agency for Health Technology Assessment in Poland? A Glimpse Into Decision Makers' Preferences.
Niewada M; Polkowska M; Jakubczyk M; Golicki D
Value Health Reg Issues; 2013; 2(2):267-272. PubMed ID: 29702876
[TBL] [Abstract][Full Text] [Related]
29. Oncology drug health technology assessment recommendations: Canadian versus UK experiences.
Chabot I; Rocchi A
Clinicoecon Outcomes Res; 2014; 6():357-67. PubMed ID: 25075196
[TBL] [Abstract][Full Text] [Related]
30. Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
Neumann D; Jabłecka A
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):781-792. PubMed ID: 26768654
[TBL] [Abstract][Full Text] [Related]
31. Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries.
Kolasa K; Kalo Z; Zah V; Dolezal T
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):283-7. PubMed ID: 22812552
[TBL] [Abstract][Full Text] [Related]
32. Which Criteria are Considered and How are They Evaluated in Health Technology Assessments? A Review of Methodological Guidelines Used in Western and Asian Countries.
Wang Y; Qiu T; Zhou J; Francois C; Toumi M
Appl Health Econ Health Policy; 2021 May; 19(3):281-304. PubMed ID: 33426626
[TBL] [Abstract][Full Text] [Related]
33. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
[TBL] [Abstract][Full Text] [Related]
34. Synergy between health technology assessments and clinical guidelines for multiple sclerosis.
Hogervorst MA; Vreman RA; Zawada A; Zielińska M; Dawoud DM; de Jong BA; Mantel-Teeuwisse AK; Goettsch WG
Clin Transl Sci; 2023 May; 16(5):835-849. PubMed ID: 36855929
[TBL] [Abstract][Full Text] [Related]
35. Methods for the comparative evaluation of pharmaceuticals.
Zentner A; Velasco-Garrido M; Busse R
GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
[TBL] [Abstract][Full Text] [Related]
36. Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries.
Blonda A; Barcina Lacosta T; Toumi M; Simoens S
Front Pharmacol; 2021; 12():750742. PubMed ID: 35126102
[No Abstract] [Full Text] [Related]
37. Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?
Adkins EM; Nicholson L; Floyd D; Ratcliffe M; Chevrou-Severac H
Clinicoecon Outcomes Res; 2017; 9():327-342. PubMed ID: 28652787
[TBL] [Abstract][Full Text] [Related]
38. Impact of health technology assessment and managed entry schemes on reimbursement decisions of centrally authorised medicinal products in Belgium.
Van Wilder P; Pirson M; Dupont A
Eur J Clin Pharmacol; 2019 Jul; 75(7):895-900. PubMed ID: 30877328
[TBL] [Abstract][Full Text] [Related]
39. Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union.
Beletsi A; Koutrafouri V; Karampli E; Pavi E
Value Health Reg Issues; 2018 Sep; 16():81-91. PubMed ID: 30316029
[TBL] [Abstract][Full Text] [Related]
40. Uncertainty tolerance among experts involved in drug reimbursement recommendations: Qualitative evidence from HTA committees in Canada and Poland.
Wranik WD; Gambold L; Peacock S
Health Policy; 2021 Mar; 125(3):307-319. PubMed ID: 33388158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
